TY  - GEN
AU  - Vilariño, N
AU  - Bruna, J
AU  - Nadal, E
AU  - Bosch-Barrera, J
AU  - Valiente, M
AU  - Vilariño, N.
AU  - Bruna, J.
AU  - Bosch-Barrera, J.
AU  - Valiente, M.
AU  - Nadal, E.
PY  - 2020
DO  - 10.1016/j.ctrv.2020.102067
SN  - 0305-7372
UR  - http://hdl.handle.net/20.500.12105/15049
AB  - Brain metastases are frequent complications in patients with non-small-cell lung cancer (NSCLC) associated with significant morbidity and poor prognosis. Our goal is to give a global overlook on clinical efficacy from immune checkpoint inhibitors in...
LA  - eng
PB  - Elsevier
KW  - Astrocytes
KW  - microglia
KW  - macrophages
KW  - lymphocytes
KW  - endothelial cells
KW  - vascular co-option
KW  - angiogenesis
KW  - immunotherapy
KW  - Animals
KW  - Antineoplastic Agents, Immunological
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - B7-H1 Antigen
KW  - Brain Neoplasms
KW  - CD8-Positive T-Lymphocytes
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Clinical Trials, Phase I as Topic
KW  - Clinical Trials, Phase II as Topic
KW  - Clinical Trials, Phase III as Topic
KW  - Humans
KW  - Lung Neoplasms
KW  - Lymphocyte Activation
KW  - Programmed Cell Death 1 Receptor
KW  - Randomized Controlled Trials as Topic
KW  - Tumor Microenvironment
TI  - Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic [Pre-print]
TY  - preprint
ER  -